| Literature DB >> 24639773 |
Cihan Cetin1, Hasan Serdaroglu2, Sitki Tuzlali3.
Abstract
BACKGROUND: Endometriosis is a disease that is hard to diagnose without the gold standard method, laparoscopy. An easier diagnostic method is needed.Entities:
Keywords: CD68 Antigen; Endometriosis; Macrophage; Neurofilament Proteins
Year: 2013 PMID: 24639773 PMCID: PMC3941416
Source DB: PubMed Journal: Iran J Reprod Med ISSN: 1680-6433
Figure 1Number of patients in endometriosis and control groups (L/S: laparoscopy, L/T: laparotomy
Operations performed
|
|
| |
|---|---|---|
|
| 25 | |
| Diagnostic | 4 (16) | |
| Operative | 21 (84) | |
| LUNA | 1 (5) | |
| Cystectomy | 16 (75) | |
| Adhesiolysis | 1 (5) | |
| LVAH+USO | 1 (5) | |
| Tubal ligation | 2 (10) | |
|
| 34 | |
| Cystectomy | 4 (11) | |
| TAH | 13 (38) | |
| TAH+ Cystectomy | 1 (2) | |
| TAH+USO | 3 (8) | |
| TAH+BSO | 14 (41) | |
L/S: laparoscopy. L/T: laparotomy. LUNA: laparoscopic uterine nerve ablation. LVAH: laparoscopy assisted vaginal hysterectomy. USO: unilateral salpingoooferectomy. BSO: bilateral salpingoooferectomy. TAH: total abdominal hysterectomy
Indications for operations in groups
|
|
|
|
|
|---|---|---|---|
| Cystoma ovarii | 29 (94) | 9 (31) | 38 (63) |
| Infertility | 1 (3) | 4 (14) | 5 (8) |
| Endometrial hyperplasia | 1 (3) | 0 | 1 (2) |
| Chronic pelvic pain | 0 | 2 (7) | 2 (3) |
| Myoma uteri | 0 | 11 (38) | 11 (18) |
| Vaginal bleedingresistant tomedical treatment | 0 | 1 (3) | 1 (2) |
| Tubal ligation | 0 | 2 (7) | 2 (3) |
| Total | 31 | 29 | 60 |
Clinical/Histological properties of patients
|
|
|
| |
|---|---|---|---|
| Age | 38.29 ± 6.34 (26-47) | 37.24 ± 5.40 (24-44) | 0.49 |
| Gravidity | 1.87 ± 1.93 (0-6) | 2.41 ± 1.88 (0-8) | 0.27 |
| Parity | 1.19 ± 1.14 (0-3) | 2.03 ± 1.64 (0-8) | 0.03* |
| Abortus | 0.68 ± 1.08 (0-3) | 0.35 ± 0.67 (0-2) | 0.15 |
|
|
|
|
|
| Proliferative | 13 (42) | 16 (55) | 29 (48) |
| Early secretory | 4 (13) | 4 (14) | 8 (13) |
| Midsecretory | 6 (19) | 2 (7) | 8 (13) |
| Late secretory | 4 (13) | 5 (17) | 9 (15) |
| Unovulatory cycles | 4 (13) | 2 (7) | 6 (10) |
| Total | 31 | 29 | 60 |
|
|
| ||
| I | 3 (10) | ||
| II | 3 (10) | ||
| III | 9 (29) | ||
| IV | 16 (51) | ||
| Total | 31 |
*Student t-test was used for comparison and (p<0.05) was accepted as statistically significant
CD68 (+) cell counts in menstruel phases and in endometriosis stages
|
|
|
| ||
|---|---|---|---|---|
|
| ||||
| Proliferative | 236.08 ± 90.57 | 174.81 ± 51.72 | 0.03* | |
| Early secretory | 204.00 ± 46.10 | 202.00 ± 34.45 | 0.95 | |
| Midsecretory | 228.83 ± 183.55 | 178.00 ± 53.74 | 0.57 | |
| Late secretory | 184.50 ± 94.01 | 156.60 ± 12.60 | 0.53 | |
| Unovulatory cycles | 175.75 ± 57.77 | 179.00 ± 7.07 | 0.92 | |
|
| ||||
| I | 154.00 ± 45.57 | 0.52 | ||
| II | 270.00 ± 96.25 | |||
| III | 212.00 ± 90.23 | |||
| IV | 219.94 ± 120.71 | |||
*statistically significant (p<0.05) **student t-test and Kruskal–Wallis chi-square test were used
Figure 2Photomicrographs taken following immunohistochemical staining for CD68 in different menstruel phases.